Last reviewed · How we verify
Recombinant EphB4-HSA Fusion Protein — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Recombinant EphB4-HSA Fusion Protein (Recombinant EphB4-HSA Fusion Protein) — AIDS Malignancy Consortium.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Recombinant EphB4-HSA Fusion Protein TARGET | Recombinant EphB4-HSA Fusion Protein | AIDS Malignancy Consortium | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Recombinant EphB4-HSA Fusion Protein CI watch — RSS
- Recombinant EphB4-HSA Fusion Protein CI watch — Atom
- Recombinant EphB4-HSA Fusion Protein CI watch — JSON
- Recombinant EphB4-HSA Fusion Protein alone — RSS
Cite this brief
Drug Landscape (2026). Recombinant EphB4-HSA Fusion Protein — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-ephb4-hsa-fusion-protein. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab